Phase 1/2a study of TTX-3360 in Huntington's disease
Latest Information Update: 28 Apr 2021
At a glance
- Drugs TTX-3360 (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; First in man
- 27 Apr 2021 According to a Triplet Therapeutics media release, the company is preparing to submit an Investigational New Drug (IND)/Clinical Trial Application (CTA) for TTX-3360 by year end.
- 23 Jul 2020 New trial record
- 21 Jul 2020 According to a Triplet Therapeutics media release, the company expects to file an IND in the second half of 2021, with an initial focus on Huntington's disease.